Rosalind Advisors Inc. Acquires New Shares in uniQure N.V. $QURE

Rosalind Advisors Inc. acquired a new position in shares of uniQure N.V. (NASDAQ:QURE) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 125,000 shares of the biotechnology company’s stock, valued at approximately $7,296,000. uniQure comprises 2.6% of Rosalind Advisors Inc.’s holdings, making the stock its 18th biggest position. Rosalind Advisors Inc. owned about 0.23% of uniQure at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Private Trust Co. NA bought a new stake in uniQure in the third quarter valued at $28,000. Jones Financial Companies Lllp grew its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,538 shares during the period. Knott David M Jr acquired a new stake in shares of uniQure in the 3rd quarter worth about $117,000. Finally, Teacher Retirement System of Texas bought a new stake in uniQure in the 2nd quarter valued at about $151,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other uniQure news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the sale, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 81,399 shares of company stock worth $1,527,645. 4.79% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on QURE shares. TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $15.00 to $60.00 in a research report on Monday. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $11.00 to $35.00 in a report on Monday. Wolfe Research began coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Barclays initiated coverage on shares of uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price for the company. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

uniQure Price Performance

NASDAQ QURE opened at $16.94 on Friday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The company has a market cap of $1.06 billion, a PE ratio of -4.91 and a beta of 0.73. The stock’s 50-day moving average price is $21.53 and its two-hundred day moving average price is $29.49.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The company had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. On average, analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Mizuho upgraded uniQure to “outperform” with a $35 price target (up from $12), and multiple firms (RBC, Wells Fargo, Chardan) issued bullish commentary or upgrades this week, supporting short-term buying interest. Mizuho upgrade / coverage roundup
• Positive Sentiment: Royal Bank of Canada and Wells Fargo raised ratings on QURE (coverage noted by AmericanBankingNews), which helped earlier session rallies and increased analyst attention ahead of key drug catalysts. RBC upgrade article
• Neutral Sentiment: Seeking Alpha published an analysis titled “A Unique Situation For UniQure” that dissects catalysts and risks; the piece may influence investors weighing upside vs. regulatory/legal risk but does not present new primary facts. A Unique Situation For UniQure
• Negative Sentiment: Hagens Berman highlighted reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” and “manipulated” data for the AMT-130 program — a serious regulatory credibility issue that increases the risk of further clinical/regulatory setbacks and fuels investor concern. Hagens Berman / FDA accusation alert
• Negative Sentiment: Multiple plaintiff law firms (Pomerantz, Bernstein Liebhard, Faruqi, Levi & Korsinsky, Rosen, Kahn Swick & Foti, ClaimsFiler) have filed or solicited investors in securities class actions and are publicizing April lead-plaintiff deadlines — raising potential litigation liability and ongoing headline risk. Pomerantz class action alert Bernstein Liebhard shareholder alert
• Negative Sentiment: HC Wainwright cut near- and multi-year earnings forecasts substantially (Q1–Q4 2026 and FY2026–FY2030 revisions), which signals weaker expected near-term financials and reduces forward EPS visibility despite the firm’s “Buy” rating — a factor pressuring valuation. HC Wainwright estimate revisions (MarketBeat summary)

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.